On 26 April 2019, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Cabazitaxel Teva, intended for the treatment of prostate cancer.
The company that applied for authorisation is Teva B.V. It may request a re-examination of the opinion within 15 days of receipt of notification of this negative opinion.
|Agency product number||
|International non-proprietary name (INN) or common name||
|Date opinion adopted||